Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
09/15/2022* -- Results Q4 2022 -- -0.41 --
05/12/2022 -- Results Q3 2022 -0.65 -0.97 32.97%
02/09/2022 -- Results Q2 2022 -0.80 -0.66 -21.52%
11/12/2021 -- Results Q1 2022 -0.92 -0.89 -3.63%
09/15/2021 -- Results Q4 2021 -0.78 -0.86 9.65%
05/17/2021 -- Results Q3 2021 -0.66 -0.78 15.90%
02/10/2021 -- Results Q2 2021 -0.88 -0.75 -17.33%
11/12/2020 -- Results Q1 2021 -0.62 -0.84 26.19%
*Estimated Date/Time

Earnings

Next Report Date 09/15/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/12/2022
Beat/Miss Upgrade
Return Since 4.62%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
URL https://www.rezolutebio.com
Investor Relations URL N/A
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Sep. 15, 2022 (est.)
Last Earnings Release May. 12, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
16.80%
-31.51%
-11.50%
-89.83%
27.78%
108.5%
-60.13%
-28.87%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.31%
-62.53%
-10.00%
45.83%
25.71%
-6.06%
6.45%
1.14%
-76.29%
--
--
-52.45%
-44.43%
-29.63%
-62.72%
-82.59%
-40.88%
--
--
--
--
--
--
--
-61.41%
--
--
--
--
--
--
--
-83.89%
As of June 24, 2022.

Profile

Edit
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
URL https://www.rezolutebio.com
Investor Relations URL N/A
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Sep. 15, 2022 (est.)
Last Earnings Release May. 12, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter RZLT Tweets